On this episode of Raise the Line, we’ll introduce you to a relatively new company in the digital health space focused on treatment-resistant mental health patients, which constitute about 30% of people in the US with a mental health diagnosis. Our guest is Jimmy Qian, the co-founder and president of Osmind, who believes mental health practitioners could benefit from a more data-driven approach. “We can't understand the biology of neuropsychiatry unless we get more and more multimodal data and work together as a scientific community to really understand how mental health even works, and that requires rethinking diagnosis and treatments from the ground up using data,” says Qian. As he tells host Shiv Gaglani, Osmind is sharing its data with researchers to help improve scientific understanding of hard-to-treat conditions and has already published two studies with Stanford, including the largest ever real-world analysis of ketamine as a treatment for depression.  Check out this informative conversation to learn how Osmind’s platform is also giving patients the opportunity to provide real-time information on how they're doing between visits and helping providers smooth out their workflow.Mentioned in this episode: https://www.osmind.org/